Literature DB >> 1584325

Mechanisms of ciclosporin A-induced vasoconstriction in the isolated perfused rat kidney.

N Mehring1, K H Neumann, K H Rahn, W Zidek.   

Abstract

Hypertension is a well-known side effect of ciclosporin A (CsA). In the present study the mechanisms of vasoconstriction in renal vessels were examined in the isolated perfused rat kidney. Kidneys were perfused with constant flow at a temperature of 37 degrees C with Tyrode's solution equilibrated with 95% O2/5% CO2. CsA was dissolved in ethanol. 500 and 2000 ng/ml increased resistance of renal vessels by 0.97 +/- 0.55 x 10(5) and 2.29 +/- 1.33 x 10(5) dyn s cm-5, respectively (mean values +/- SD, n = 12). The vasoconstriction developed gradually over 4 min. The vasopressor effect of CsA was not changed by saralasin (10(-6) M), nifedipine (10(-6) M) and ketanserin (10(-6) M), but was completely blocked by phentolamine and prazosin (each 10(-6) M). CsA-induced vasoconstriction was not prevented by perfusion with Ca(2+)-free solution containing 2 mmol EGTA. Similarly, pretreatment with reserpine to deplete sympathetic nerve endings from catecholamines did not affect CsA-induced vasoconstriction. The findings suggest that CsA-induced vasoconstriction is mediated by stimulation of alpha 1-receptors. Ca2+ influx does not play a role for CsA-induced vasoconstriction. Prolonged perfusion of rat kidneys with the vehicle cremophor EL elicits an irreversible increase in perfusion pressure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1584325     DOI: 10.1159/000186812

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain.

Authors:  H Sanchez; J Zoll; X Bigard; V Veksler; B Mettauer; E Lampert; J Lonsdorfer; R Ventura-Clapier
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  HEGPOL: randomized, placebo controlled, multicenter, double-blind clinical trial to investigate hepatoprotective effects of glycine in the postoperative phase of liver transplantation [ISRCTN69350312].

Authors:  Steffen P Luntz; Kristina Unnebrink; Monika Seibert-Grafe; Hartwig Bunzendahl; Thomas W Kraus; Markus W Büchler; Ernst Klar; Peter Schemmer
Journal:  BMC Surg       Date:  2005-08-17       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.